| Document |
Document Title |
|
WO/2008/125615A1 |
The present invention is directed towards new 18F-folate radiopharmaceuticals, wherein fluorine-18 is covalently linked through a triazole- or tetrazole linker to a folate or derivative thereof, a method of their preparation, as well as ...
|
|
WO/2008/123891A1 |
The present invention discloses pteridinone derivatives for use as inhibitors of stearoyl-CoA desaturase having the structure of Formula (I) The compounds are useful in treating and/or preventing various human diseases, mediated by stear...
|
|
WO/2008/120766A1 |
[PROBLEMS] To provide an analgesic composition which is more safe compared to a conventional analgesic agent and exhibits an analgesic activity at the same or higher level compared to a conventional analgesic agent. [MEANS FOR SOLVING PR...
|
|
WO/2008/116742A1 |
The invention is concerned with novel aza-pyridopyrimidinone derivatives of formula (I) wherein R1, R2, R3, R4, R5, X1, X2, X3, Y, Z, m and n are as defined in the description and in the claims, as well as physiologically acceptable salt...
|
|
WO/2008/114009A1 |
This invention pertains generally to the field of G-quadruplex ligands, and more particularly, to certain 10H-benzo[g]pteridine-2,4-dione compounds ("BPD compounds"), as described herein, which, inter alia, (selectively) bind (and stabil...
|
|
WO/2008/093075A2 |
The present invention relates to compounds that inhibit HSP90 function, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufactur...
|
|
WO/2008/089008A2 |
Disclosed herein are analogs of tetrahydrobiopterin, compositions containing the same, and methods of treating an individual suffering from a condition responsive to tetrahydrobiopterin by administration of the analog. These analogs are ...
|
|
WO/2008/088909A1 |
This invention is in the field of chemical restructuring of antimetabolite agents known to have poor oral bioavailability and to cause tissue toxicity as a side effect, by producing their orotate derivatives. More particularly, it concer...
|
|
WO/2008/076392A2 |
The present invention relates to compounds useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of v...
|
|
WO/2008/061456A1 |
The present invention discloses a new biguanidine compound, i.e. folacin-metformin, and its manufacture with inorganic salt of metformin as raw material. Compared with metformin, the compound has the same clinic curative effect, such as ...
|
|
WO/2008/050078A1 |
Compounds of formula (I) are inhibitors of Polo-like kinases (PLKs), and are useful, inter alia, in the treatment of proliferative diseases: wherein R1 is hydrogen, or a (C1C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl or (C3-C6)cycloalkyl gr...
|
|
WO/2008/050096A1 |
Compound of formula (I) are inhibitors of Polo-like kinases (PLKs), and are useful in treatment of cell proliferative diseases: wherein R1 and R2 are hydrogen, or an optionally substituted (C1-C6)alkyl, (C2- C6)alkenyl, (C2-C6)alkynyl or...
|
|
WO/2008/051494A1 |
Provided herein are Heteroaryl Compounds having the following structure: (I) wherein R1, R2, L, X, Y, Z, Q, A and B are as defined herein, compositions comprising an effective amount of a Heteroaryl Compound and methods for treating or p...
|
|
WO/2008/031284A1 |
A process for preparation of calcium (6S)-5- methyltetrahydrofolate, including the following steps: resolution of racemic (6R,S)-5-methyltetrahydrofolic acid using α-phenethylamine to obtain (6S)-5- methyltetrahydrofolic acid and salifi...
|
|
WO/2008/009909A1 |
There is provided a compound of formula (I) : or a pharmaceutically acceptable salt thereof. Processes for the manufacturing thereof and uses in therapy.
|
|
WO/2008/009079A2 |
The invention provides 4,6-di- and 2,4,6-tri-substituted pteridine derivatives with a specific substitution pattern which exhibit a significant and selective activity against certain types of viral infections, in particular selectively i...
|
|
WO/2008/003149A2 |
Tri-substituted pteridines and tetra-substituted pteridines exhibit a significant and selective activity against certain types of viral infections, in particular they selectively inhibit the replication of the hepatitis C virus, and are ...
|
|
WO/2007/135026A2 |
The invention relates to novel pteridines, suitable for the treatment of airway or gastrointestinal complaints or diseases, inflammatory diseases of the joints, the skin or eyes, diseases of the peripheral or central nervous systems, or ...
|
|
WO/2007/135374A1 |
Compounds of formula (I), or optionally the pharmacologically acceptable acid addition salts thereof, and their use in the inhibition of PLK activity are described.
|
|
WO/2007/135027A1 |
The invention relates to novel pteridines of formula (1), suitable for the treatment of airway or gastrointestinal complaints or diseases, inflammatory diseases of the joints, the skin or eyes, diseases of the peripheral or central nervo...
|
|
WO/2007/127366A2 |
Compositions and methods and are provided for treating disorders associated with compromised vasculostasis. Invention methods and compositions are useful for treating a variety of disorders including for example, stroke, myocardial infar...
|
|
WO/2007/119367A1 |
Tetrahydrobiopterin (BH4) to be used as a pharmaceutical has an excellent efficacy, therefore, expansion of use or application thereof is considered. However, because BH4 is expensive and unstable to oxidation, its application to other t...
|
|
WO/2007/119889A1 |
Disclosed is a compound represented by the general formula [I] shown below, a pharmaceutically acceptable salt thereof, or a solvate of the compound or the salt. Also disclosed are an anti-HCV agent and an HCV polymerase inhibitor each c...
|
|
WO/2007/110340A2 |
This invention is concerned with compounds of the formula (I) wherein A, R1 to R5 and G are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical composit...
|
|
WO/2007/105023A1 |
Methods of screening and designing compounds as inhibitors of glutamine synthetase, including adenylylated glutamine synthetase, are provided herein. Compounds and compositions useful for the treatment, prevention, and/or amelioration of...
|
|
WO/2007/090844A1 |
The present invention relates to a specific salt of a dihydropteridione derivative, namely the trihydrochloride salt of the compound N-[trans-4-[4-(cyclopropylmethyl)-1- piperazinyl]cyclohexyl]-4-[[(7R)-7-ethyl-5,6,7,8-tetrahydro-
5-meth...
|
|
WO/2007/089538A1 |
Methods are provided for preparation of compositions having an enhanced level of soluble alloxazine, as compared to compositions prepared using conventional techniques. Compositions and a riboflavin form having higher solubility in solut...
|
|
WO/2007/060404A1 |
There is provided compounds of formula (I), which are suitable for the treatment of cancer.
|
|
WO/2007/049736A1 |
This invention provides a process for producing a natural product having stable quality with high recovery. There is also provided a method for concentration-crystallizing a natural product, characterized by comprising continuously measu...
|
|
WO/2007/021234A1 |
The present invention relates to novel boron-comprising compounds, to pharmaceutical compositions comprising said compounds, to the therapeutic use of said compounds, and to a process for preparation of said compounds. The compounds are ...
|
|
WO/2007/020277A2 |
he invention relates to compounds of the formula I, or pharmaceutically acceptable salts thereof: wherein: Z = O or S; B = -NR2-, -CH2NR2-, -CH2CH2NR2-, -CH2CHR7- or -CH2O-, wherein R2 is H or a C1-3 alkyl, alkenyl or alkynyl group, and ...
|
|
WO/2007/000648A1 |
Disclosed are formulations in the form of mouthwashes, gingival gels, toothpastes or other forms suitable for topical buccal administration containing colostrum and folates as active ingredients. The compositions according to the inventi...
|
|
WO/2006/120251A1 |
The present invention relates to the use of pteridines as inhibitors of HCV replication as well as their use in pharmaceutical compositions aimed to treat or combat HCV infections. In addition, the present invention relates to compounds ...
|
|
WO/2006/112772A1 |
There is provided a combination product comprising: (A) BH4, a functional derivative or biosynthetic precursor thereof, or a pharmaceutically-acceptable derivative of BH4 or its derivative or precursor; and (B) an inhibitor of the biosyn...
|
|
WO/2006/112495A1 |
ABSTRACT A method for selectively producing stable alpha form crystals of sapropterin hydrochloride is provided. In this method, the alpha form crystal of sapropterin hydrochloride is produced by dissolving sapropterin hydrochloride with...
|
|
WO/2006/101845A2 |
Methods for purifying pteroic acid, analogs of pteroic acid, and derivatives of pteroic acid are described. Methods for synthesizing and purifying conjugates of vitamins, including FITC conjugates of folic acid, folic acid analogs, and d...
|
|
WO/2006/090848A1 |
A method for determining an effect of methotrexate in a rheumatoid arthritis patient and a method for determining the amount to be administered to the patient before the administration, both characterized by detecting a single nucleotide...
|
|
WO/2006/070902A1 |
To provide a method for producing L-biopterin on a large industrial scale by using a reagent which is inexpensive and easy to handle, without requiring a use of any particular equipment or plants. A method for producing a biopterin deriv...
|
|
WO/2006/065703A1 |
The present invention provides compounds having the formula: (I) wherein A-B together represents one of the following structures; (II), (III), (IV) and n, R1, R2, R3, R4, L1, L2, Y and Z are as defined in classes and subclasses herein, a...
|
|
WO/2006/058868A2 |
The invention relates to novel pteridines which can be used in the treatment of respiratory or gastrointestinal complaints or diseases, joint, skin or eye inflammatory diseases, diseases of the periphery or central nervous system or canc...
|
|
WO/2006/058867A2 |
The invention relates to novel pteridines which are suitable for the treatment of respiratory or gastro-intestinal complaints or diseases, inflammatory diseases of joints, skin or eyes, diseases of the peripheral or central nervous syste...
|
|
WO/2006/058869A2 |
The invention relates to novel pteridines which are suitable for treating respiratory or gastrointestinal complaints or diseases, joint, skin or eye inflammatory diseases, disease of the periphery or central nervous system or cancer. The...
|
|
WO/2006/058876A1 |
The invention relates to a method for producing the annelated piperazin-2-one derivatives of general formula (I), wherein R1 to R5, A1 and A2 are defined as in the claims and the description. The invention especially relates to the produ...
|
|
WO/2006/058669A2 |
The present invention relates to aminotetrahydropteridines and processes for the manufacture thereof. In particular, the present invention relates to a process for the manufacture of aminotetrahydrobiopterine. Said compound is an inhibit...
|
|
WO/2006/056607A1 |
The invention relates to novel pteridines, which are suitable for treating respiratory tract or gastro-intestinal complaints or diseases, inflammatory diseases of the joints, skin, or eyes, diseases of the peripheral or central nervous s...
|
|
WO/2006/021548A1 |
The invention relates to novel dihydropteridinones of general formula (I), wherein the radicals R1 to R5, Ra to Rc, W, Q1, and Q2 have the meanings indicated in the claims and the description, the isomers thereof, and the use thereof for...
|
|
WO/2006/021547A1 |
The invention relates to compounds of general formula (1), wherein L, Q1, Q2, X, Y, Ra, Rb, Rc, R1, R2, R3, and R4 are defined as indicated in claim 1. Said compounds are suitable for the treatment of diseases characterized by excessive ...
|
|
WO/2006/021379A1 |
The invention relates to novel dihydropteridinones of general formula (I), in which the radicals L, R1, R2, R3, R4 and R5 have the meanings cited in the claims and description, to isomers thereof, methods for producing these dihydropteri...
|
|
WO/2006/021378A1 |
The invention relates to novel dihydropteridinones of general formula (I), in which the radicals L, R1, R2, R3, R4 and R5 have the meanings cited in the claims and description, to isomers thereof, methods for producing these dihydropteri...
|
|
WO/2006/018222A1 |
The invention relates to novel hydrates and novel polymorphs of 4-[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6
-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl
) benzamide, methods for the production thereof, an...
|
